表紙
市場調查報告書

神經退化性疾病的新治療藥物:第I部分 - 阿茲海默症和帕金森氏症的新標靶治療策略技術

Emerging Therapeutics for Neurodegenerative Diseases, Part I: Novel Targeted Therapeutic Strategies Technologies for Alzheimer's and Parkinson's Diseases

出版商 Frost & Sullivan 商品編碼 910112
出版日期 內容資訊 英文 110 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
神經退化性疾病的新治療藥物:第I部分 - 阿茲海默症和帕金森氏症的新標靶治療策略技術 Emerging Therapeutics for Neurodegenerative Diseases, Part I: Novel Targeted Therapeutic Strategies Technologies for Alzheimer's and Parkinson's Diseases
出版日期: 2019年08月23日內容資訊: 英文 110 Pages
簡介

本報告研究阿茲海默症和帕金森氏症的新治療藥物趨勢,分析疾病背景和概要、新治療藥物種類和概要、藥劑開發現況和課題、市場潛力、企業和企業間行動、影響市場的各種因素等情報。

第1章 摘要整理

第2章 神經退化性疾病:技術環境和趨勢

  • 現況和課題
  • 多因性發病
  • 併行觸發因素
  • 新興治療藥物
  • 補助醫療

第3章 神經退化性疾病的新治療法

  • 治療和診斷解決方案:PROTAC
  • 神經退化性治療:標靶蛋白質配位體
  • 治療和診斷解決方案:類□
  • 神經退化性治療:類□方法
  • 神經退化性治療:聚集抑制劑
  • 神經退化性治療:細胞信號傳達調節
  • 神經退化性治療:仿生神經保護劑
  • 神經退化性治療:炎症調節劑
  • 神經退化性治療:影像診斷生物標記
  • 神經退化性治療:類□介入
  • 治療和診斷解決方案:幹細胞/基因療法
  • 神經退化性治療:細胞療法的開發
  • 治療和診斷解決方案:腸道微生物群
  • 神經退化性治療:腸道微生物群介入
  • 治療和診斷解決方案:奈米技術、前驅藥、Codrug
  • 治療和診斷解決方案:大麻二酚
  • 神經退化性治療:預防和管理

第4章 技術現況:概要和評估

  • 神經退化性臨床前模型:需求和複雜性
  • 神經退化性模型的缺點:阿茲海默症
  • 神經退化性模型的缺點:帕金森氏症
  • 治療技術現況
  • 阿茲海默症治療藥物開發情況
  • 帕金森氏症治療藥物開發情況

第5章 技術雷達智能解決方案

  • 緩和治療到未來策略
  • 新治療策略和初步成果
  • 推動臨床試驗的單株抗體
  • 強化自噬的藥理製劑
  • 阿茲海默症:具潛力的候選分子藥物
  • 帕金森氏症:主要企業

第6章 市場潛力和技術導入

  • 神經退化性疾病市場的潛力
  • 對整體環境的影響因素
  • 產業合作:SWOT分析
  • 神經退化性疾病的合作框架
  • 概要:商業合作和技術能力
  • 透過合作創製確定目標

第7章 商業環境和智慧財產權

  • 對業務開發的實用影響
  • 對業務和流程的影響
  • 技術轉移評估

第8章 附錄

  • 藥劑PIPELINE:阿茲海默症
  • 藥劑PIPELINE:帕金森氏症

第9章 產業聯絡資訊

  • 主要產業影響者
  • 免責聲明
目錄
Product Code: D8BB

Novel Targeted Therapeutic Strategies Technologies Around Neurodegenerative Disorders - From Palliative to Future Interventions

At present, only a few therapies are available with relatively low success. Both, the clinical and the scientific communities are critically devoted to develop new therapeutic approaches to treat and diagnose neurodegenerative diseases.

At present days, neurodegenerative diseases represent one of the main causes of death in the industrialized economy. Overall characterized by a loss of neurons in particular regions of the nervous system, the subsequent decline in cognitive and motor function that patients experience in these diseases is associated with nerve cell loss.

The most common denominator among neurodegenerative diseases, in addition to nerve cell loss is inflammation. Although, a series of mutant genes and environmental toxins are related to neurodegenerative disorders, the causal mechanisms remain poorly understood.

Neurodegenerative diseases can be defined as multifactorial debilitating disorders of the nervous system. Overall, neurodegenerative diseases affect approximately 30 million individuals worldwide, according to the World Health Organization (WHO).

Factors Contributing to Neurodegenerative Diseases

The factors contributing to the onset of neurodegenerative diseases are multiple. Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS) diseases are well-established as the consequence of misfolding and dysfunctional trafficking of proteins. However, other factors including mitochondrial dysfunction, oxidative stress, aging, and environmental issues are deeply associated with the onset of neurodegeneration.

Molecular Mechanisms Underlying Neurodegeneration

Although all these factors have been demonstrated to significantly contribute to the etiology of common neurodegenerative diseases, some molecular mechanisms underlying neurodegeneration remain unveiled.

Present efforts are focused on the identification of viable drug targets and biomarkers for early diagnosis of the diseases, in order to develop the best suited therapies.

  • Some Multifactorial Conditions to Watch
  • Abnormal protein dynamics
  • Defective protein degradation and aggregation
  • Oxidative stress
  • Free radical formation
  • Impaired bioenergetics
  • Mitochondrial dysfunction
  • Exposure to toxic metals and pesticides
  • Others
  • Coverage of Neurodegenerative Diseases Technologies

This research service, ‘Emerging Therapeutics for Neurodegenerative Diseases', focuses on the leading technology and business trends that are making possible the implementation of cutting-edge innovations that help to face the present and future challenges of the neurodegenerative disease therapeutics sector.

The tendencies depicted in this study will help to drive the sustainability of the neurodegenerative disease therapeutics industry by directly exhibiting the principal challenges faced by leading biopharmaceutical and biotechnology companies to develop new product modalities in an affordable and high performance style, while getting market acceptance and achieving market leadership by translating technology innovation to market competitiveness

The study covers the following topics:

  • Technology roadmap, trends, capabilities, and applications targeted
  • Stakeholder activities, influence, industry initiatives, investment environment, and funding support
  • Regional and global regulation landscape and standardization approaches for tackling challenges
  • Technology benchmarking for smart decisions

An appendix is included, comprising lists of major industry influencers found in the field.

Table of Contents

1.0. Executive Summary

  • 1.1. Facts and Findings: Neurodegenerative Diseases
  • 1.2. Research Focus: Neurodegenerative Diseases
  • 1.3. Research Scope: Foreseeing Challenges and Solutions
  • 1.4. Analysis Framework: Frost & Sullivan's Core Value
  • 1.5. Research Methodology

2.0. Technology Landscape and Trends

  • 2.1. Neurodegenerative Diseases: Facts and Challenges
  • 2.2. Neurodegenerative Diseases: Multifactorial Onset
  • 2.3. Neurodegenerative Diseases: Concurrent Triggering Factors
  • 2.4. Neurodegenerative Diseases: Emerging Therapies
  • 2.5. Neurodegenerative Diseases: Complementary Therapies

3.0. Emerging Therapies to Address Neurodegeneration

  • 3.1. Therapeutic and Diagnostic Solutions: PROTACs
  • 3.2. Neurodegenerative Therapies: Targeting Protein Ligands
  • 3.3. Therapeutic and Diagnostic Solutions: Peptoids
  • 3.4. Neurodegenerative Therapies: Five Peptoid Approaches
  • 3.5. Neurodegenerative Therapies: Aggregation Inhibitors
  • 3.6. Neurodegenerative Therapies: Cell Signaling Modulators
  • 3.7. Neurodegenerative Therapies: Biomimetic Neuroprotectors
  • 3.8. Neurodegenerative Therapies: Inflammation Regulators
  • 3.9. Neurodegenerative Therapies: Imaging Diagnostics Biomarkers
  • 3.10. Neurodegenerative Therapies: Summary of Peptoid Interventions
  • 3.11. Therapeutic and Diagnostic Solutions: Stem Cell/Gene Therapies
  • 3.12. Neurodegenerative Therapies: Cell Therapy Developments
  • 3.13. Therapeutic and Diagnostic Solutions: Gut Microbiome
  • 3.14. Neurodegenerative Therapies: Gut Microbiome Interventions
  • 3.15. Therapeutic and Diagnostic Solutions: Nanotech, Prodrug, and Codrug
  • 3.16. Therapeutic and Diagnostic Solutions: Cannabidiols
  • 3.17. Neurodegenerative Therapies: Prevention and Management

4.0. Technology Status Review and Assessment

  • 4.1. Neurodegenerative Preclinical Models: Needs and Complexities
  • 4.2. Neurodegenerative Models' Pitfalls: Alzheimer's Disease
  • 4.3. Neurodegenerative Models' Pitfalls: Parkinson's Disease
  • 4.4. Present Status of Therapeutics Technology
  • 4.5. Alzheimer's Disease Drug Development Status
  • 4.5. Alzheimer's Disease Drug Development Status (continued)
  • 4.5. Alzheimer's Disease Drug Development Status (continued)
  • 4.5. Alzheimer's Disease Drug Development Status (continued)
  • 4.5. Alzheimer's Disease Drug Development Status (continued)
  • 4.6. Parkinson's Disease Drug Development Status

5.0. Technology Radar Intelligent Solutions

  • 5.1. From Palliative Treatment to Future Strategies
  • 5.2. New Treatment Strategies and Preliminary Outcomes
  • 5.2. New Treatment Strategies and Preliminary Outcomes (continued)
  • 5.3. Monoclonal Antibodies Advancing Clinical Trials
  • 5.4. Pharmacological Agents Enhancing Autophagy
  • 5.5. Top Promising Candidates for Alzheimer's Disease
  • 5.6. Parkinson's Disease Top Companies

6.0. Market Potential and Technology Adoption

  • 6.1. Neurodegenerative Diseases Market Potential
  • 6.2. Overall Environmental Impact Factors
  • 6.3. Best-fit Industry Partnerships: SWOT Analysis
  • 6.4. Collaborative Framework for Neurodegenerative Diseases
  • 6.5. Overview of Business Partnerships and Technology Capabilities
  • 6.6. Key Aspects to Target through Collaborative Initiatives

7.0. Business Landscape and Intellectual Property Analysis

  • 7.1. Actionable Impact on Business Development
  • 7.2. Repercussions on Businesses and Processes
  • 7.3. Technology Transfer Assessment

8.0. Appendix

  • 8.1. Alzheimer's Disease Drug Pipeline
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.2. Parkinson's Disease Drug Pipeline
  • 8.2. Parkinson's Disease Drug Pipeline (continued)

9.0. Key Industry Contacts

  • 9.1. Key Industry Influencers
  • 9.1. Key Industry Influencers (continued)
  • 9.1. Key Industry Influencers (continued)
  • 9.1. Key Industry Influencers (continued)
  • 9.1. Key Industry Influencers (continued)
  • Legal Disclaimer
Back to Top